Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) insider John Militello sold 833 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $22.87, for a total value of $19,050.71. Following the completion of the sale, the insider now owns 54,406 shares of the company’s […]
China Universal Asset Management Co. Ltd. lifted its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 404.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,424 shares of the biotechnology company’s stock after buying an additional 8,356 shares during the […]
The Goldman Sachs Group started coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $39.00 price target on the biotechnology company’s stock. RCKT has been the topic of several other reports. UBS Group cut their price objective […]
China Universal Asset Management Co. Ltd. boosted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 404.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,424 shares of the biotechnology company’s stock after buying an […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $65.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 123.91% from the stock’s previous close. […]